MEP45308A - [1,8] naftiridin-2-oni i srodna jedinjenja za liječenje šizofrenije - Google Patents

[1,8] naftiridin-2-oni i srodna jedinjenja za liječenje šizofrenije

Info

Publication number
MEP45308A
MEP45308A MEP-453/08A MEP45308A MEP45308A ME P45308 A MEP45308 A ME P45308A ME P45308 A MEP45308 A ME P45308A ME P45308 A MEP45308 A ME P45308A
Authority
ME
Montenegro
Prior art keywords
treatment
naphthyridin
schizophrenia
ones
related compounds
Prior art date
Application number
MEP-453/08A
Other languages
English (en)
Inventor
Jerry Clark
Jamie Davis
David Favor
Lorraine Fay
Lloyd Franklin
Kevin Henegar
Douglas Johnson
Brian Nichelson
Ligong Ou
Joseph Thomas Repine
Michael Walters
Andrew David White
Zhijian Zhu
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34216117&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP45308(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MEP45308A publication Critical patent/MEP45308A/bs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Ovaj pronalazak se odnosi na jedinjenja formule 1 gdje su G, A, Z, Q, X, Y, i R1 i R2 definisani kao u opisu, farmaceutske kompozicije koje ih sadrže i upotrebu u liječenju centralnog nervnog sistema i drugih poremećaja.
MEP-453/08A 2003-08-22 2004-08-13 [1,8] naftiridin-2-oni i srodna jedinjenja za liječenje šizofrenije MEP45308A (bs)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49737003P 2003-08-22 2003-08-22
PCT/IB2004/002665 WO2005019215A1 (en) 2003-08-22 2004-08-13 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
RSP-2006/0129A RS20060129A (en) 2003-08-22 2004-08-13 /1,8/naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Publications (1)

Publication Number Publication Date
MEP45308A true MEP45308A (bs) 2011-02-10

Family

ID=34216117

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-453/08A MEP45308A (bs) 2003-08-22 2004-08-13 [1,8] naftiridin-2-oni i srodna jedinjenja za liječenje šizofrenije

Country Status (36)

Country Link
US (3) US7160888B2 (bs)
EP (1) EP1660497A1 (bs)
JP (1) JP4034811B2 (bs)
KR (2) KR100765668B1 (bs)
CN (1) CN100422181C (bs)
AP (1) AP2006003525A0 (bs)
AR (1) AR045386A1 (bs)
AU (1) AU2004266191B2 (bs)
BR (1) BRPI0413860A (bs)
CA (1) CA2538915C (bs)
CR (2) CR8254A (bs)
CU (1) CU23464B7 (bs)
EA (1) EA009645B1 (bs)
EC (1) ECSP066391A (bs)
GE (1) GEP20084447B (bs)
GT (1) GT200500007A (bs)
HK (1) HK1091815A1 (bs)
HN (1) HN2004000319A (bs)
IL (1) IL173439A0 (bs)
IS (1) IS8267A (bs)
MA (1) MA28003A1 (bs)
ME (1) MEP45308A (bs)
MX (1) MXPA06002070A (bs)
MY (1) MY140693A (bs)
NL (1) NL1026892C2 (bs)
NO (1) NO20060324L (bs)
NZ (1) NZ545078A (bs)
OA (1) OA13238A (bs)
PA (1) PA8609701A1 (bs)
PE (1) PE20051039A1 (bs)
RS (1) RS20060129A (bs)
TN (1) TNSN06063A1 (bs)
TW (1) TWI298327B (bs)
UA (1) UA82541C2 (bs)
WO (1) WO2005019215A1 (bs)
ZA (1) ZA200601526B (bs)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
ES2323451T7 (es) 2001-07-20 2011-08-01 Psychogenics Inc. Tratamiento para el trastorno de hiperactividad con deficit de atencion.
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
MXPA06013944A (es) 2004-06-08 2007-10-08 Neurosearch Sweden Ab Nuevas fenilpiperidinas/piperazinas disustituidas como moduladores de la neurotransmision de dopamina.
PT1773772E (pt) * 2004-06-08 2010-10-04 Nsab Af Neurosearch Sweden Ab Novas fenilpiperidinas/piperazinas dissubstituídas como moduladores de neurotransmissão de dopamina
US7851629B2 (en) 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
MX2007004215A (es) 2004-10-13 2007-12-12 Neurosearch Sweden Ab Proceso para la sintesis de 4-(3-metansulfonilfenil)-1-n- propilpiperidina.
FR2877005A1 (fr) * 2004-10-22 2006-04-28 Bioprojet Soc Civ Ile Nouveaux derives d'arylpiperazine
WO2006081289A2 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
WO2006090272A1 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia
WO2006090273A2 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
EA200701856A1 (ru) * 2005-04-01 2008-02-28 Уорнер-Ламберт Компани Ллс Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
JP4193949B2 (ja) * 2005-04-08 2008-12-10 ファイザー・プロダクツ・インク Ｉ型グリシン輸送阻害剤としての二環式［３．１．０］ヘテロアリールアミド
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI329641B (en) 2005-08-31 2010-09-01 Otsuka Pharma Co Ltd (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
US8247408B2 (en) 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
WO2007052104A2 (en) * 2005-10-31 2007-05-10 Pfizer Products Inc. Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-but oxy]-3,4-dihydro-1h-[1,8]naphthyridin-2-one
EP2520567A3 (en) * 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
WO2007116265A1 (en) * 2006-03-31 2007-10-18 Pfizer Products Inc. Process for making a tetrahydro-pyridoazepin-8-one compound
MX2008014450A (es) 2006-05-18 2009-03-09 Mannkind Corp Inhibidores de cinasa intracelular.
AP2710A (en) * 2006-09-15 2013-07-30 Pfizer Prod Inc Pyrido (2, 3-D) Pyrimidinone compounds and their use as P13 inhibitors
US20100093738A1 (en) * 2006-10-06 2010-04-15 Basf Se Fungicidal Compounds and Fungicidal Compositions
WO2008047883A1 (en) * 2006-10-13 2008-04-24 Otsuka Pharmaceutical Co., Ltd. Piperazine-substituted benzothiophenes for treatment of mental disorders
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
WO2008084324A1 (en) * 2007-01-04 2008-07-17 Pfizer Products Inc. Naphthyridinone compound
JP4785881B2 (ja) * 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
CL2008001002A1 (es) 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
AU2008254585B2 (en) * 2007-05-21 2013-09-26 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
PA8781801A1 (es) * 2007-05-30 2009-01-23 Wyeth Corp Derivados heteroarilo antidepresivos de benzodioxanos heterociclo-fusionados
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
RU2492169C2 (ru) 2007-12-18 2013-09-10 Актелион Фармасьютиклз Лтд Производные 5-аминоциклилметилоксазолидин-2-она
EP2322520A4 (en) 2008-07-28 2012-04-25 Jiangsu Guohua Invest Co Ltd ARALKYL-SUBSTITUTED PIPERIDINE OR PIPERAZINE DERIVATIVES AND USES THEREOF FOR THE TREATMENT OF SCHIZOPHRENIA
MY153622A (en) 2008-07-31 2015-02-27 Senomyx Inc Processes and intermediates for making sweet taste enhancers
PL2376497T3 (pl) 2008-12-12 2014-03-31 Idorsia Pharmaceuticals Ltd Pochodne 5-amino-2-(1-hydroksyetylo)tetrahydropiranu
SG172958A1 (en) * 2009-01-23 2011-08-29 Takeda Pharmaceutical Poly (adp-ribose) polymerase (parp) inhibitors
WO2010099502A1 (en) * 2009-02-26 2010-09-02 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of utilizing arylpiperazine derivatives
US8686009B2 (en) 2009-06-25 2014-04-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
RS56352B2 (sr) * 2009-06-25 2023-02-28 Alkermes Pharma Ireland Ltd Heterociklična jedinjenja za lečenje neuroloških i psiholoških poremećaja
EP2566329B1 (en) 2010-05-04 2020-09-09 Alkermes Pharma Ireland Limited Process for synthesizing oxidized lactam compounds
ES2691671T3 (es) 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
WO2012003418A2 (en) * 2010-07-02 2012-01-05 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine d2 receptors
MA34836B1 (fr) 2010-12-17 2014-01-02 Hoffmann La Roche Composes heterocycliques azotes 6;6- condenses substitues et leurs utilisations
LT3156056T (lt) 2011-03-18 2024-02-26 Alkermes Pharma Ireland Limited Farmacinės kompozicijos, apimančios sorbitano esterius
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
CA2856749A1 (en) 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
JP5952912B2 (ja) 2011-12-15 2016-07-13 アルカーメス ファーマ アイルランド リミテッド 二級アミン化合物のプロドラッグ
EP2827867B1 (en) 2012-03-19 2019-11-06 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
AU2013235519C1 (en) 2012-03-19 2018-04-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
JP6333802B2 (ja) 2012-03-19 2018-05-30 アルカームス ファーマ アイルランド リミテッド ベンジルアルコールを含む医薬組成物
EP2844346B1 (en) 2012-04-04 2020-01-01 Prilenia Neurotherapeutics Ltd. Pharmaceutical compositions for combination therapy
EP2847193B1 (en) * 2012-05-09 2019-08-07 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
EP2897592B1 (en) 2012-09-19 2020-02-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
CN106132415A (zh) 2014-03-20 2016-11-16 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
CN104785295B (zh) * 2015-03-18 2018-03-06 杭州创培信息科技有限公司 一种高选择性多巴胺铂炭催化剂的制备方法
US9902703B2 (en) 2015-07-01 2018-02-27 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
PL3386511T3 (pl) 2015-12-10 2021-11-08 Ptc Therapeutics, Inc. Sposoby leczenia choroby huntingtona
CN106242934A (zh) * 2016-07-26 2016-12-21 云南民族大学 一种酮的β‑位C‑H键乙酰氧化合成方法
MX2019014514A (es) * 2017-06-05 2020-07-20 Ptc Therapeutics Inc Compuestos para tratar la enfermedad de huntington.
EP3644996B1 (en) 2017-06-28 2023-07-26 PTC Therapeutics, Inc. Methods for treating huntington's disease
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
US20210017174A1 (en) 2018-03-07 2021-01-21 Bayer Aktiengesellschaft Identification and use of erk5 inhibitor
EA202092001A1 (ru) 2018-03-27 2021-01-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения болезни гентингтона
CA3103976A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
EP3814360A1 (en) 2018-06-27 2021-05-05 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
BR112021002261A2 (pt) 2018-08-07 2021-05-04 Firmenich Incorporated 2,2-dióxidos de 4-amino-1h-benzo[c][1,2,6]tiadiazina 5-substituídos e formulações e usos dos mesmos
AU2019322538B2 (en) * 2018-08-13 2021-09-30 F. Hoffmann-La Roche Ag New heterocyclic compounds as monoacylglycerol lipase inhibitors
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
TW202115024A (zh) 2019-08-14 2021-04-16 美商英塞特公司 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
BR112022002375A2 (pt) 2019-09-12 2022-07-19 Hoffmann La Roche Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl
CA3157681A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
CN114634479A (zh) * 2020-12-16 2022-06-17 北京盈科瑞创新药物研究有限公司 一种派嗪衍生物、其制备方法及应用
WO2022212538A1 (en) * 2021-03-31 2022-10-06 Blueprint Medicines Corporation Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN116891465A (zh) * 2022-03-30 2023-10-17 苏州旺山旺水生物医药有限公司 一类n-取代的喹啉酮化合物、其制备方法和用途
CN114805081A (zh) * 2022-05-20 2022-07-29 都创(上海)医药开发有限公司 一种基于微通道连续流技术快速制备1-萘胺的方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5649361A (en) 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
JPH07165720A (ja) * 1988-10-31 1995-06-27 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
WO1990006303A1 (en) 1988-12-02 1990-06-14 Pfizer Inc. Arylpiperidine derivatives
ES2076253T3 (es) 1989-05-19 1995-11-01 Hoechst Roussel Pharma N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
US5350747A (en) 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
WO1991000863A1 (en) * 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
US5032598A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
MX9201991A (es) 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
IE914218A1 (en) 1991-09-11 1993-03-24 Mcneilab Inc Novel 4-arylpiperazines and 4-arylpiperidines
US5206366A (en) 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
DK0674631T3 (da) 1992-12-17 2000-04-10 Pfizer Substituerede pyrazoler som CRF-antogonister
RU2142946C1 (ru) 1992-12-17 1999-12-20 Пфайзер Инк. Производные пиразола и фармацевтическая композиция, содержащая их
JP2895961B2 (ja) 1992-12-17 1999-05-31 フアイザー・インコーポレイテツド Ｃｒｆアンタゴニストとしてのピロロピリミジン
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
FR2699918B1 (fr) 1992-12-30 1995-03-17 Pf Medicament Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments.
JPH07247271A (ja) * 1994-01-21 1995-09-26 Otsuka Pharmaceut Co Ltd ３，４−ジヒドロカルボスチリル誘導体
FR2731222A1 (fr) 1995-03-02 1996-09-06 Pf Medicament Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments
JP2987484B2 (ja) * 1995-03-16 1999-12-06 大塚製薬 株式会社 カルボスチリル誘導体の製造方法
JP2900130B2 (ja) * 1995-03-16 1999-06-02 大塚製薬株式会社 カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US6114334A (en) 1995-07-13 2000-09-05 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
WO1997014419A1 (en) 1995-10-20 1997-04-24 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
JPH09241161A (ja) 1996-03-08 1997-09-16 Nippon Shinyaku Co Ltd 医 薬
US5912256A (en) 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
FR2761071B1 (fr) 1997-03-20 1999-12-03 Synthelabo Derives de quinolein-2(1h)-one et de dihydroquinolein-2(1h)- one, leur preparation et leur application en therapeutique
FR2769912B1 (fr) 1997-10-16 2000-03-10 Pf Medicament Nouveaux derives de la 3-oxo- (2h)-1,2,4 triazine leur preparation et leur application en therapeutique humaine
DE19747063A1 (de) 1997-10-24 1999-04-29 Basf Ag 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung
US6267784B1 (en) 1998-05-01 2001-07-31 Benz Research And Development Corporation Intraocular lens and haptics made of a copolymer
US6844344B2 (en) 1999-12-20 2005-01-18 Eli Lilly And Company Benzofuran derivatives
DE10041574A1 (de) 2000-08-24 2002-03-07 Merck Patent Gmbh Chromenonderivate
AU2002243394A1 (en) 2000-11-16 2002-06-24 Wyeth Aryloxy piperidinyl derivatives for the treatment of depression
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
SK652004A3 (en) 2001-06-29 2004-09-08 Lundbeck & Co As H Heteroaryl derivatives, pharmaceutical composition with the content thereof and use of the same
GB0227240D0 (en) 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
TW200507841A (en) 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Also Published As

Publication number Publication date
AR045386A1 (es) 2005-10-26
BRPI0413860A (pt) 2006-10-24
CA2538915A1 (en) 2005-03-03
US20060287310A1 (en) 2006-12-21
KR20070053364A (ko) 2007-05-23
NZ545078A (en) 2009-09-25
ECSP066391A (es) 2006-08-30
EP1660497A1 (en) 2006-05-31
TWI298327B (en) 2008-07-01
GEP20084447B (en) 2008-08-10
AU2004266191B2 (en) 2009-11-26
NO20060324L (no) 2006-05-18
EA200600294A1 (ru) 2006-08-25
ZA200601526B (en) 2007-04-25
CU23464B7 (es) 2009-12-17
NL1026892C2 (nl) 2005-11-21
CA2538915C (en) 2010-06-15
CN100422181C (zh) 2008-10-01
KR20060071404A (ko) 2006-06-26
IL173439A0 (en) 2006-06-11
KR100801794B1 (ko) 2008-02-05
MXPA06002070A (es) 2006-05-19
CR8254A (es) 2006-10-17
KR100765668B1 (ko) 2007-10-10
JP2007503386A (ja) 2007-02-22
UA82541C2 (uk) 2008-04-25
GT200500007A (es) 2005-10-24
TNSN06063A1 (en) 2007-10-03
AU2004266191A1 (en) 2005-03-03
US7160888B2 (en) 2007-01-09
OA13238A (en) 2006-12-13
JP4034811B2 (ja) 2008-01-16
CR9834A (es) 2008-04-21
RS20060129A (en) 2008-06-05
EA009645B1 (ru) 2008-02-28
IS8267A (is) 2006-01-26
US20050043309A1 (en) 2005-02-24
CN1839134A (zh) 2006-09-27
AP2006003525A0 (en) 2006-02-28
HN2004000319A (es) 2010-06-09
MA28003A1 (fr) 2006-07-03
PE20051039A1 (es) 2005-12-12
NL1026892A1 (nl) 2005-02-28
MY140693A (en) 2010-01-15
PA8609701A1 (es) 2005-05-24
TW200524938A (en) 2005-08-01
WO2005019215A1 (en) 2005-03-03
HK1091815A1 (en) 2007-01-26
US20060287309A1 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
MEP45308A (bs) [1,8] naftiridin-2-oni i srodna jedinjenja za liječenje šizofrenije
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
HRP20041042A2 (en) Novel substituted sulfamate anticonvulsant derivatives
ME00595B (me) 2-okso-1-pirolidinski derivati, postupci za njihovo dobijanje i njihove primene
PT1259489E (pt) Compostos azapoliciclicos condensados con arilo.
SE0102616D0 (sv) Novel compounds
NZ539841A (en) Hydroxyethylamine derivatives for the treatment of alzheimer's disease
DK1725536T3 (da) Imidazolin-derivater med CB1-antagonistisk aktivitet
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
WO2006055434A3 (en) Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
SE0301446D0 (sv) New Compounds
TW200740781A (en) Novel compounds
CR9182A (es) Derivado de quinolina, su uso, preparacion y medicamento que lo contiene
EA200701856A1 (ru) Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
SE0300092D0 (sv) Novel compounds
MA28286A1 (fr) Dérivés de 1-N-phenyl-amino-1H-imidazole et compositions pharmaceutiques les contenant
SE0300091D0 (sv) Novel compounds
MXPA05004273A (es) Derivados de fenilalquil y piridilalquil piperazina.
YU44301A (sh) 5ht1 antagonisti za antidepresantnu terapiju
BR0314796A (pt) Piperazinas substituìdas heterocìclicas para o tratamento de esquizofrenia
TW200833696A (en) Spiro-piperidine derivatives
BRPI0416739A (pt) derivados de indano substituìdo heterocìclico e compostos afins para o tratamento de esquizofrenia
MX2009010729A (es) Derivados de dihidro-benzo[b] [1,4]diazepin-2-ona-sulfonamida.
BR0000901A (pt) Derivados 4-fenil-4-heteroarilpiperidina
SE0004099D0 (sv) Novel compounds